CN113710320A - 硫辛酸前药 - Google Patents

硫辛酸前药 Download PDF

Info

Publication number
CN113710320A
CN113710320A CN202080028809.9A CN202080028809A CN113710320A CN 113710320 A CN113710320 A CN 113710320A CN 202080028809 A CN202080028809 A CN 202080028809A CN 113710320 A CN113710320 A CN 113710320A
Authority
CN
China
Prior art keywords
same
different
substituted
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080028809.9A
Other languages
English (en)
Chinese (zh)
Inventor
加藤雅智
小田知子
高冈慎治
本田崇宏
畑龙也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN113710320A publication Critical patent/CN113710320A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080028809.9A 2019-04-17 2020-04-16 硫辛酸前药 Pending CN113710320A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-078798 2019-04-17
JP2019078798 2019-04-17
PCT/JP2020/016774 WO2020213693A1 (ja) 2019-04-17 2020-04-16 リポ酸プロドラッグ

Publications (1)

Publication Number Publication Date
CN113710320A true CN113710320A (zh) 2021-11-26

Family

ID=72837203

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080028809.9A Pending CN113710320A (zh) 2019-04-17 2020-04-16 硫辛酸前药

Country Status (9)

Country Link
US (1) US20220151989A1 (cg-RX-API-DMAC7.html)
EP (1) EP3957365A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2020213693A1 (cg-RX-API-DMAC7.html)
KR (1) KR20220002965A (cg-RX-API-DMAC7.html)
CN (1) CN113710320A (cg-RX-API-DMAC7.html)
AU (1) AU2020258729A1 (cg-RX-API-DMAC7.html)
CA (1) CA3136938A1 (cg-RX-API-DMAC7.html)
TW (1) TW202103696A (cg-RX-API-DMAC7.html)
WO (1) WO2020213693A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117263907A (zh) * 2023-09-23 2023-12-22 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208035A (zh) * 1997-04-02 1999-02-17 三共株式会社 二硫戊环衍生物,其制备以及它们的治疗作用
WO2009111633A2 (en) * 2008-03-05 2009-09-11 Encore Health, Llc Mercaptan and seleno-mercaptan compounds and methods of using them
WO2010054135A1 (en) * 2008-11-07 2010-05-14 Encore Health, Llc Low dose lipoic acid pharmaceutical compositions and methods
WO2010147957A2 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
WO2010147962A1 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
CN106455563A (zh) * 2014-03-03 2017-02-22 安可视觉公司 硫辛酸胆碱酯组合物及使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11269170A (ja) * 1997-04-02 1999-10-05 Sankyo Co Ltd ジチオラン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208035A (zh) * 1997-04-02 1999-02-17 三共株式会社 二硫戊环衍生物,其制备以及它们的治疗作用
WO2009111633A2 (en) * 2008-03-05 2009-09-11 Encore Health, Llc Mercaptan and seleno-mercaptan compounds and methods of using them
WO2010054135A1 (en) * 2008-11-07 2010-05-14 Encore Health, Llc Low dose lipoic acid pharmaceutical compositions and methods
WO2010147957A2 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
WO2010147962A1 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
CN106455563A (zh) * 2014-03-03 2017-02-22 安可视觉公司 硫辛酸胆碱酯组合物及使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117263907A (zh) * 2023-09-23 2023-12-22 江西科技师范大学 一种丙酮酸脱氢酶e2抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
US20220151989A1 (en) 2022-05-19
EP3957365A4 (en) 2023-01-11
TW202103696A (zh) 2021-02-01
KR20220002965A (ko) 2022-01-07
CA3136938A1 (en) 2020-10-22
EP3957365A1 (en) 2022-02-23
JPWO2020213693A1 (cg-RX-API-DMAC7.html) 2020-10-22
AU2020258729A1 (en) 2021-11-11
WO2020213693A1 (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
JP6602802B2 (ja) Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
US10112922B2 (en) Inhibitor of bruton's tyrosine kinase
BRPI0611966B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
EA015971B1 (ru) Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
CN117337289A (zh) 用于治疗脑病症的四环化合物
CN108779090A (zh) 2环性杂环化合物
CN113164421A (zh) 含有4-苯基丁酸的老视的治疗或预防剂
CN113710320A (zh) 硫辛酸前药
JP2010514733A (ja) 高眼圧症の治療のためのイソソルビドモノニトレート誘導体
CA3214066A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
ES2368199T3 (es) Derivados covalentes de alcanolamidas de ácidos monocarboxílicos y dicarboxílicos funcionalmente activos en el receptor cannabinoide cb2.
JP2016056207A (ja) プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
TWI721697B (zh) 用於治療骨關節炎的化合物
EP4197540A1 (en) Drug formulation containing sepetaprost
US20240383906A1 (en) 5-substituted pyridine-2(1h)-ketone compound and use thereof
JP2024509267A (ja) リボソーム障害に関連する貧血を処置するための組成物および方法
WO2023058673A1 (ja) 老視等の治療または予防に有用な含硫黄化合物
US12215109B2 (en) Crystal of pyrazolo[3,4-d]pyrimidine
KR20230015955A (ko) 노시의 치료 또는 예방에 유용한 황 함유 화합물
WO2026012523A2 (zh) 钠通道调节剂
JP2025520705A (ja) 眼疾患治療において使用するためのトリアゾール類
JP2025518700A (ja) グリシン輸送阻害剤を用いて肝性ポルフィリン症を処置するための組成物および方法
WO2025079741A1 (ko) 항노화용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211126

WD01 Invention patent application deemed withdrawn after publication